Effect of Repetitive Transcranial Direct Current Stimulation (tDCS) on Chronic Pelvic Pain
1 other identifier
interventional
24
1 country
1
Brief Summary
We will rigorously test whether modulation of the motor cortex by transcranial direct current stimulation (tDCS) is an effective treatment for patients with chronic pelvic pain through the following specific aims: A) The primary aim of this study is to determine whether transcranial direct current stimulation applied to the motor cortex in patients with chronic pelvic pain induces a significant decrease in the pain or symptoms as compared with sham tDCS. We will also measure changes in the clinical symptom scores of multiple pelvic organs, drug intake (narcotic), anxiety, depression, traumatic stress, as well as overall improvement in the quality of life to assess the effects of this treatment. B) Determine the duration of the clinical effects of tDCS. We will therefore compare the amelioration of pain and related symptoms between active and sham tDCS for one year following treatment. C) Determine whether tDCS changes the threshold for pain detection as compared with sham tDCS. Patients with chronic pelvic pain have a lower threshold for pain as compared to healthy subjects and we hypothesized that this threshold will increase after stimulation with tDCS. D) Finally, we will examine whether 5 days of tDCS treatment is safe for use in chronic pelvic pain patients. Safety will be assessed through neuropsychological tests and adverse event reporting.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jan 2009
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 2, 2007
CompletedFirst Posted
Study publicly available on registry
November 6, 2007
CompletedStudy Start
First participant enrolled
January 1, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2009
CompletedSeptember 18, 2009
September 1, 2009
5 months
November 2, 2007
September 17, 2009
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Patient Global Assessment (PGA):
2 weeks
Visual analog scale (VAS) for pain:
2 weeks
Secondary Outcomes (1)
Interstitial cystitis symptom index:
2 weeks
Study Arms (2)
A
ACTIVE COMPARATORDuring each session, the anode electrode will be placed on the motor cortex (contralateral to the most \[or predominant\] painful side \[or the side where the symptoms begin or the left as a default\]) and the cathode will be placed over the contralateral supraorbital area. In active tDCS subjects, 1 mA of transcranial direct current stimulation will be applied for 30 minutes.
C
PLACEBO COMPARATORFor sham-controlled tDCS subjects, the same montage will be used; however current will be applied only for 30 seconds.
Interventions
During each session, the anode electrode will be placed on the motor cortex (contralateral to the most \[or predominant\] painful side \[or the side where the symptoms begin or the left as a default\]) and the cathode will be placed over the contralateral supraorbital area. In active tDCS subjects, 1 mA of transcranial direct current stimulation will be applied for 30 minutes.
Eligibility Criteria
You may qualify if:
- Subjects must be females between 18 and 55 years of age.
- Subjects must have a current VAS for pelvic pain of 5 or more.
You may not qualify if:
- Known pelvic malignancy.
- Patients with major depression with suicidal risk as clinically defined.
- Patients with other known, uncontrolled neuropsychiatric disorders.
- Abnormal neurological examination other than as signs of the condition studied in the present protocol.
- Contraindication to tDCS:
- A history of unmanaged substance abuse or dependence within the last 6 months.
- A history of previous treatment with tDCS.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Summa Health System
Akron, Ohio, 44309, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Bradford W Fenton, MD, PhD
Summa Health System
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
November 2, 2007
First Posted
November 6, 2007
Study Start
January 1, 2009
Primary Completion
June 1, 2009
Study Completion
June 1, 2009
Last Updated
September 18, 2009
Record last verified: 2009-09